BlossomHill Therapeutics, Inc. Statistics
Want to see BLSM full AI Analyst Report?
BlossomHill Therapeutics, Inc. (BLSM) Stock Statistics & Valuation Metrics
Total Valuation
BlossomHill Therapeutics, Inc. has a market cap or net worth of $445.62M. The enterprise value is $386.93M.
- Market Cap
- $445.62M
- Enterprise Value
- $386.93M
Share Statistics
BlossomHill Therapeutics, Inc. has 31,784,908 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,784,908
- Owned by Insiders
- 55.71%
- Owned by Institutions
- 9.81%
Financial Efficiency
BlossomHill Therapeutics, Inc.’s return on equity (ROE) is 0.46 and return on invested capital (ROIC) is -43.41%.
- Return on Equity (ROE)
- 0.46
- Return on Assets (ROA)
- -0.37
- Return on Invested Capital (ROIC)
- -43.41%
- Return on Capital Employed (ROCE)
- -0.43
- Revenue Per Employee
- 0
- Profits Per Employee
- -877.61K
- Employee Count
- 69
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BlossomHill Therapeutics, Inc. is -1.30. BlossomHill Therapeutics, Inc.’s PEG ratio is -0.01.
- PE Ratio
- -1.30
- PS Ratio
- 0.00
- PB Ratio
- 12.32
- Price to FCF
- -6.14
- Price to Operating Cash Flow
- -39.20
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, BlossomHill Therapeutics, Inc. had revenue of 0 and earned -60.55M in profits. Earnings per share was -2.08.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -64.02M
- Pretax Income
- -60.55M
- Net Income
- -60.55M
- EBITDA
- -63.58M
- Earnings Per Share (EPS)
- -2.08
Cash Flow
In the last 12 months, operating cash flow was -66.36M and capital expenditures -13,000, giving a free cash flow of -66.37M billion.
- Operating Cash Flow
- -66.36M
- Free Cash Flow
- -66.37M
- Free Cash Flow per Share
- -0.36
Dividends & Yields
BlossomHill Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -16.28%
- Earnings Yield
- -2.64%
Stock Price Statistics
- Beta
- 1.08
- 52-Week Price Change
- -12.38%
- 50-Day Moving Average
- 18.16
- 200-Day Moving Average
- 17.93
- Relative Strength Index (RSI)
- 44.70
- Average Volume (3m)
- 189.41K
Important Dates
BlossomHill Therapeutics, Inc. upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
BlossomHill Therapeutics, Inc. as a current ratio of 8.97, with Debt / Equity ratio of -17.00%
- Current Ratio
- 8.97
- Quick Ratio
- 8.97
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.80
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BlossomHill Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BlossomHill Therapeutics, Inc. EV to EBITDA ratio is -2.85, with an EV/FCF ratio of -3.10.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.85
- EV to Free Cash Flow
- -3.10
- EV to Operating Cash Flow
- -3.10
Balance Sheet
BlossomHill Therapeutics, Inc. has $224.91M in cash and marketable securities with $23.10M in debt, giving a net cash position of $201.81M billion.
- Cash & Marketable Securities
- $224.91M
- Total Debt
- $23.10M
- Net Cash
- $201.81M
- Net Cash Per Share
- $6.35
- Tangible Book Value Per Share
- $1.14
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for BlossomHill Therapeutics, Inc. is $36.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $36.75
- Price Target Upside
- 162.13% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- 49
